Keros Therapeutics (KROS) Insider buying
4 open-market purchases of KROS by Keros Therapeutics's executives and directors since May 2026, worth $41,650 in total, from SEC Form 4 filings.
Summary
The most recent: Jean Jacques Bienaime, Director bought $10,270 on August 17, 2026.
The biggest buyer over the period is Jean Jacques Bienaime (Director): 4 purchases, $41,650.
By year
| Year | Purchases | Value |
|---|---|---|
| 2026 | 4 | $41,650 |
Biggest buyers
| Insider | Buys | Value |
|---|---|---|
| Jean Jacques Bienaime Director | 4 | $41,650 |
Every purchase
Newest first. From SEC Form 4 filings. Insider buying across the market.
| Date | Insider | Shares | Price | Value | Filing |
|---|---|---|---|---|---|
| Aug 17, 2026 | Jacques Bienaime Jean Director |
1,000 | $10.27 | $10,270 | Form 4 |
| Jul 15, 2026 | Jacques Bienaime Jean Director |
1,000 | $10.61 | $10,610 | Form 4 |
| Jun 15, 2026 | Jacques Bienaime Jean Director |
1,000 | $10.19 | $10,190 | Form 4 |
| May 15, 2026 | Jacques Bienaime Jean Director |
1,000 | $10.58 | $10,580 | Form 4 |
Questions about Keros Therapeutics
Are Keros Therapeutics insiders buying the stock?
4 open-market purchases of KROS by Keros Therapeutics's executives and directors since May 2026, worth $41,650 in total, from SEC Form 4 filings. The most recent: Jean Jacques Bienaime, Director bought $10,270 on August 17, 2026.
What counts as insider buying here?
Open-market purchases (Form 4 code P) by officers and directors. Option exercises, grants and purchases by 10% owners are left out.
From Keros Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.